Prednisone Active Not Recruiting Phase 4 Trials for Metastatic Hormone Refractory Prostate Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02485691Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent